Sci Rep:包含活性基质前列腺癌组织的代谢和转录组分析

2018-10-10 AlexYang MedSci原创

活性基质是一种组织特性,通常在前列腺癌的肿瘤微环境中观察到,并且与恶性肿瘤相关。最近,有研究人员在完全相同的前列腺癌组织样本中,检测了活性氧基质包含物中差异表达的基因和代谢物质。研究人员利用组织病理学评估了来自43名前列腺切除术后患者的108份冷冻的前列腺癌样本活性氧基质。研究人员在部分样本中利用高分辨率魔角旋转磁共振光谱(HR-MAS MRS)he RNA芯片分别分析了代谢物(n=85)和转录组

活性基质是一种组织特性,通常在前列腺癌的肿瘤微环境中观察到,并且与恶性肿瘤相关。最近,有研究人员在完全相同的前列腺癌组织样本中,检测了活性氧基质包含物中差异表达的基因和代谢物质。

研究人员利用组织病理学评估了来自43名前列腺切除术后患者的108份冷冻的前列腺癌样本活性氧基质。研究人员在部分样本中利用高分辨率魔角旋转磁共振光谱(HR-MAS MRS)he RNA芯片分别分析了代谢物(n=85)和转录组变异(n=78)情况。研究人员根据不少于5年的跟踪调查结果评估了无复发生存(n=38),并利用生化复发(BCR)作为终点,并利用多元代谢组学和基因表达分析比较了低(不大于15%)和高活性基质(不小于16%)包含物。研究发现,在前列腺癌患者的患者中,高活性基质包含物与BCR相关(Cox风险比例分析,p=0.013);且在考虑到等级组影响时结论一致。在具有高活性基质包含物中,与免疫功能和细胞外基质(ECM)重建有关的代谢物和基因均显著上调。

最后,研究人员指出,考虑到免疫机制和前列腺癌中的ECM,这些发现的进一步确定对阐释新的生物标记和药物靶标是重要的。另外,高活性基质分级与BCR有关,该事实进一步支持了组织病理学检查在临床整合中的必要性。

原始出处:

Maria K. Andersen, Kjersti Rise, Guro F. GiskeØdegård et al. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma. Sci Rep. 24 Sep 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757126, encodeId=2ebf1e571261b, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Aug 09 23:47:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747331, encodeId=fcfd1e47331b7, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Sep 17 08:47:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654136, encodeId=9c3c1654136cf, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Sat Jun 01 11:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420184, encodeId=92a1142018497, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Oct 12 04:47:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757126, encodeId=2ebf1e571261b, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Aug 09 23:47:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747331, encodeId=fcfd1e47331b7, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Sep 17 08:47:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654136, encodeId=9c3c1654136cf, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Sat Jun 01 11:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420184, encodeId=92a1142018497, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Oct 12 04:47:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
    2019-09-17 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757126, encodeId=2ebf1e571261b, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Aug 09 23:47:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747331, encodeId=fcfd1e47331b7, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Sep 17 08:47:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654136, encodeId=9c3c1654136cf, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Sat Jun 01 11:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420184, encodeId=92a1142018497, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Oct 12 04:47:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757126, encodeId=2ebf1e571261b, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Aug 09 23:47:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747331, encodeId=fcfd1e47331b7, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Tue Sep 17 08:47:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654136, encodeId=9c3c1654136cf, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Sat Jun 01 11:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420184, encodeId=92a1142018497, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Fri Oct 12 04:47:00 CST 2018, time=2018-10-12, status=1, ipAttribution=)]

相关资讯

Prostate Cancer P D:化疗后转移去势难治性前列腺癌男性在恩杂鲁胺治疗期间,雄激素阻断治疗重要性分析

恩杂鲁胺能够显著的延长转移去势难治性前列腺癌(mCRPC)患者的生存时间。然而,在mCRPC患者中继续急性雄激素阻断治疗(ADT)方面还缺乏相关证据。最近,有研究人员分析了在进行了化疗的mCRPC患者中,在恩杂鲁胺治疗期间伴随ADT治疗的效果与影响。研究人员回顾性的分析了232名mCRPC患者的医疗记录,他们在化疗后接受了口服恩杂鲁胺治疗(160?mg每天)。时间地点分别为2014年到2016年之

Oncogene:肌醇聚磷酸酯4-磷酸酶II型调控雄激素受体的活性

晚期前列腺癌中AR的激活和转录重组总是与2个肿瘤抑制因子,INPP4B和PTEN的功能丧失同时发生,上述2个肿瘤抑制因子在人类和小鼠前列腺上皮中高表达。虽然AR信号通过PTEN的调控已经被多个研究组阐释,但是否INPP4B功能的丧失影响AR的活性仍旧不清楚。最近,有研究人员利用前列腺癌细胞系,展示了INPP4B能够调控AR转录活性和致瘤信号途径Akt和PKC。在前列腺癌患者群体中基因表达的分析表明

CLIN CANCER RES:肿瘤干细胞与巨噬细胞相互作用促进前列腺癌进展和耐药

肿瘤干细胞(CSC)有助于前列腺癌的进展和去势治疗(ADT)耐药。CSC依赖于其特定的肿瘤环境,包括肿瘤相关的巨噬细胞(TAM)。理解CSC和TAM之间的相互作用可能有助于抑制前列腺癌的进展和ADT耐药。CLIN CANER RES近期发表了一篇文章研究这一问题。

ANN ONCOL:MiCaP模型可以预测前列腺癌患者术后结局

目前需要可以预测前列腺癌(PC)预后的新分子生物标志物。ANN ONCOL近期发表了一篇文章,研究了一种新的4-miRNA预后比率模型在前列腺癌中的预后作用。

FDA认定rucaparib作为前列腺癌突破性疗法资格

Clovis Oncology公司10月2日宣布,Rubraca (rucaparib)用于单药治疗既往接受过抗雄激素受体疗法以及紫杉烷类化疗的BRCA1/2+成人转移性去势抵抗前列腺癌(mCRPC)已被FDA授予突破性疗法资格。rucaparib之前也被FDA授予过单药治疗特定晚期卵巢癌患者的突破性疗法资格,并且在2016年12月19日被FDA批准用于单药治疗既往接受过两种以上化疗的BRCA突变

Oncogene:PDZ结合激酶和雄激素受体相互反馈能够驱使前列腺癌发生

阐释雄激素受体(AR)活性增加和随后恶性前列腺癌(PrCa)发展的潜在的机制在发展新的理论方面是非常关键的。最近,有研究人员利用系统生物学的方法,分析了AR调控的蛋白组,并坚定了一个新的AR调控的蛋白-PDZ结合激酶(PBK),该蛋白能够在PrCa中调节全程AR和AR变异体的活性。PBK在恶性PrCa中的过表达与早期生化复发和不良临床结果相关。除了碳末端配体结合区域,PBK还可以与AR的氮末端反式